Get started
Author

Suyu Liu

Observed name: S Liu
ORCID: 0000-0003-0126-2646
Observed ORCID: 0000-0003-0126-2646
OpenAlex ID: A5014493533
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer
2013 · S Yao, L E Sucheston, et al. · The Pharmacogenomics Journal · 32
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial
2026 · Alexander D. Sherry, Cara Haymaker, et al. · Journal of Clinical Oncology · 7
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
2026 · Alexander D. Sherry, Van To, et al. · European Urology · 2
Abstract OT3-05-04: Phase II study of atezolizumab, cobimetinib, and eribulin in patients with recurrent or metastatic inflammatory breast cancer (IBC)
2019 · A Alexander, AN Marx, et al. · Cancer Research · 2
Clinical and translational analysis of a phase Ib/II combination of atezolizumab, cobimetinib, and eribulin (ACE) to demonstrate inflammatory and metabolic programs define divergent response states.
2026 · Elyse R. Lopez, Angela Alexander, et al. · Journal of Clinical Oncology · 1
PDF
Metastasis-directed therapy with or without pembrolizumab for oligometastatic clear cell renal cell carcinoma: Pooled analysis of two prospective single-arm phase II trials.
2026 · Alexander Dean Sherry, Van To, et al. · Journal of Clinical Oncology
PDF
P4-09-09: Expression of c-MET and Phospho c-MET in Breast Cancers by Subtype and Its Impact on Survival Outcomes.
2011 · KP Raghav, W Wang, et al. · Cancer Research
Works count: 7
Citation count: 43
H-index: 2
I10-index: 1
Year
Topic
Type